4

Notice of Allowability	Application No.	Applicant(s)
	10/690,779	TAKEUCHI ET AL.
	Examiner	Art Unit
	John S. Chu	1752
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. A This communication is responsive to 9/27/06.		
2. The allowed claim(s) is/are <u>1-3 and 5-20</u> .		
 3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. Notice of Informal Page 1. Interview Summary Paper No./Mail Date 7. Examiner's Amendm 8. Examiner's Stateme 9. Other	(PTO-413), e

Application/Control Number: 10/690,779

Art Unit: 1752

Page 2

REASONS FOR ALLOWANCE

- 1. The following is an examiner's statement of reasons for allowance: The claimed invention is drawn to the following:
 - 1. (currently amended): A recording material comprising: on a support, a recording layer including a diazo compound, a coupler compound that can react with the diazo compound to form a color, and a metal salt, wherein

the coupler compound is represented by the general formula (1):

General formula (1)

$$\begin{array}{c|c}
R^{2} & & R^{5} & R^{6} \\
R^{3} & & & R^{4} & & R^{9} & R^{8}
\end{array}$$

wherein R¹, R², R³, and R⁴ each independently represent a hydrogen atom, an alkyl group, an aryl group, an alkoxy group, or an amino group; R⁵, R⁶, R⁷, R⁸, and R⁹ each independently represent one selected from the group consisting of a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an alkoxy group, an alkoxycarbonyl group, and an acyl

or a nitro group; any of R¹ to R⁹ may have a substituent; and X represents an oxygen atom or a sulfur atom.

The amendment to claim 1 removes the rejection wherein the benzothiazole in PIERROT et al contains a nitro substituted group on the phenyl ring which is now excluded from General formula (1). None of the prior art discloses or anticipates the recited recording material comprising said benzothiazole compound as a coupler and accordingly, claims 1-3, 5-20 are seen as allowable and passed to issue.

Application/Control Number: 10/690,779

Art Unit: 1752

Any comments considered necessary by applicant must be submitted no later than the

Page 3

payment of the issue fee and, to avoid processing delays, should preferably accompany the issue

fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for

Allowance."

2. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Examiner Chu whose telephone number is (571) 272-1329. The

examiner can normally be reached on Monday - Friday from 9:30 am to 6:00 pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's

supervisor, Cynthia Kelly, can be reached on (571) 272-1526

The fax phone number for the USPTO is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PMR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner, Group 1700

J.Chu

December 11, 2006